Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00736944 | Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer | completed | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02606916 | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. | completed | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04525066 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | completed | Phase 2 | 39 | Ayhman Al AfifOTHER | 0 | Aug 25, 2020 | clinicaltrials |
| NCT02776137 | Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 91 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03187314 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | completed | Phase 2 | 25 | Hangzhou Cancer HospitalOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02124707 | Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | completed | Phase 2 | 14 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT02347813 | Preventing Squamous Cell Skin Cancer | completed | Phase 2 | 12 | University of RochesterOTHER | 0 | Jun 23, 2020 | clinicaltrials |
| NCT01198028 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03433027 | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Benitec Biopharma, Inc.INDUSTRY | 2 | Apr 15, 2020 | clinicaltrials |
| NCT00957853 | Preoperative Treatment With Cetuximab and/or IMC-A12 | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01697800 | A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02882308 | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.(OPHELIA) | completed | Phase 2 | 41 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT01796821 | Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | completed | Phase 2 | 138 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01998542 | Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck(HNC) | completed | Phase 2 | 12 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 175 | Celldex TherapeuticsINDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01774760 | Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer | completed | Phase 2 | 10 | Turku University HospitalOTHER_GOV | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02794077 | Cyclophosphamide for Nasopharyngeal Carcinoma | completed | Phase 2 | 56 | The University of Hong KongOTHER | 0 | Oct 2, 2019 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT02454179 | Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma(KEYNOTE147) | completed | Phase 2 | 78 | Acerta Pharma BVINDUSTRY | 1 | Sep 12, 2019 | clinicaltrials |
| NCT01581970 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | completed | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT00126555 | Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00025233 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00389727 | Simultaneous Integrated Boost (SIB)- IMRT | completed | Phase 2 | 22 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jul 15, 2019 | clinicaltrials |
| NCT01016769 | Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00894413 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00652080 | An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) | completed | Phase 1 / Phase 2 | 35 | BPGbioINDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01696955 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00500760 | Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer | completed | Phase 2 | 153 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01941992 | Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients(ROSAM) | completed | Phase 2 | 120 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01218048 | ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 40 | Robert FerrisOTHER | 1 | Aug 16, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 23, 2020source: clinicaltrials